Verona Pharma News and Resources
Oct 21, 2024 · Stay updated with Verona Pharma's latest news and resources. Access materials to follow our progress in developing treatments for respiratory diseases and understand our journey and impact in tackling these conditions.
Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
News & SEC Filings - Verona Pharma
Oct 21, 2024 · Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update. Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion ...
Verona Pharma | Innovative Respiratory Treatments
May 9, 2024 · Verona Pharma develops novel treatments like ensifentrine in COPD. Future development is focused on chronic lung diseases such as COPD, asthma, and cystic fibrosis. Explore our advancements, patient insights, and latest investor news.
Verona Pharma Press Releases & Updates
Oct 21, 2024 · Follow Verona Pharma’s latest updates through our press releases. Stay informed on financial results, strategic financing, clinical developments, and upcoming presentations as we advance respiratory treatments.
Verona Pharma Announces $650 Million Strategic Financing with …
May 9, 2024 · The agreements provide non-dilutive capital and additional financial flexibility ahead of Verona Pharma’s planned US launch of ensifentrine and will support the Company’s continued growth.
Investor Relations | Verona Pharma
Oct 21, 2024 · Learn about Verona Pharma's innovative respiratory treatments and latest financial updates. Explore our investor presentation, recent results, and news for insights into our progress and company performance.
Verona Pharma Pipeline | Advancing Respiratory Therapies
Explore Verona Pharma's portfolio of investigational therapeutics with the goal of having a major impact on the treatment of chronic respiratory diseases.
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE …
Sep 30, 2024 · Presenter: Emily Wan, MD, Brigham and Women’s Hospital and Harvard Medical School. Session: Emerging Treatments in Obstructive Lung Disease. Oral presentation: Ensifentrine improved lung function in patients with moderate to severe COPD: a pooled analysis from the Phase 3 ENHANCE trials.
Verona Pharma Reports First Quarter 2024 Financial Results and …
Jun 26, 2024 · LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.